報價延遲最少15分鐘:2026/02/12 02:38 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.86 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-6.27/-5.40
|
|
企業價值
49.07M
|
| 資產負債 |
|
每股賬面淨值
1.90
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis. |
